NASDAQ · Biotechnology · USD

AC Immune SA (ACIU) Stock Analysis

AC Immune SA (ACIU) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ACIU

$2.47

−$0.02 (−0.80%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACIU with… →

ACIU Key Statistics

As of Oct 21, 2026

Trading

Open: $2.46
Previous Close: $2.49
Day's Range: 2.46–2.52
52-Week Range: 2.10–4.00
Volume: 88.98K
Beta: 1.55

Valuation

Market Cap: $245.58M
P/E Ratio: unprofitable
Forward P/E: 4.12
P/S ratio: 14.03
EPS (ttm): −0.54

Financials (FY)

Revenue (FY): $3.57M−86.92%
Net Income (FY): −$70.45M
Profit margin: −246.48%
Shares Outstanding: 99.43M
1-Year Return: −11.47%

Dividend and dates

Earnings Date: November 4, 2026estimated
Avg Volume: 197.04K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ACIU closed at $2.47, −11.47% over 1 year.

AC Immune SA (ACIU) has a market capitalization of $245.58M.

In fiscal 2025, ACIU reported revenue of $3.57M.

ACIU Stock Return by Calendar Year

AC Immune SA (ACIU) 10-year return: what $10,000 became

1 year: $10,000 $8,853; −11.47%
5 years: $10,000 $4,089; −59.11%
10 years: $10,000 $1,575; −84.25%

If you had invested $10,000 in AC Immune SA (ACIU) 10 years ago, at the close on October 21, 2016, it would have been worth $1,575 at the close on October 21, 2026: −84.25% in total, −16.87% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−58.79%+145.10%−21.34%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−21.34%
2025	+16.30%
2024	−46.00%
2023	+145.10%
2022	−58.79%
2021	−4.26%
2020	−39.32%
2019	−9.84%
2018	−26.17%
2017	−1.39%
2016 (partial year)	−17.11%

As of October 21, 2026.

ACIU Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$3.57M	−$70.45M	−1,971.6%
2024	$27.31M	−$50.92M	−186.4%
2023	$14.80M	−$54.23M	−366.4%
2022	$3.94M	−$70.75M	−1,798.0%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$3.57M	—	−$68.86M	−$70.45M	−1,971.6%
2024	$27.31M	—	−$52.38M	−$50.92M	−186.4%
2023	$14.80M	—	−$53.62M	−$54.23M	−366.4%
2022	$3.94M	—	−$70.85M	−$70.75M	−1,798.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACIU Valuation vs Biotechnology Median

Median of 608 stocks

Metric	ACIU	Biotechnology median	vs median
P/S ratio	14.03	13.30	5% above
Profit margin	−246.48%	−38.31%	208.2 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

The market values AC Immune SA (ACIU) at $245.58M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 90.

Over the past 52 weeks the price has ranged from $2.10 to $4.00. The most recent close on file for ACIU is $2.47, dated October 21, 2026. That is −$0.02 (−0.80%) against the previous close. The latest close sits 17.9% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.57M. That is −86.92% against the prior fiscal year, when revenue was $27.31M. The same year closed with a net loss of $70.45M. Profit margin runs at −246.48%. That is 208.2 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.54.

Across the 4 fiscal years on file, revenue moves from $3.94M in 2022 to $3.57M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 4.12. The price-to-sales ratio is 14.03. On price-to-sales that is 5.47% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −11.47%. Across 10 years the annualized return works out at −16.87%. Beta against the wider market is reported at 1.55. Annualized volatility over the trailing 10 years is 78.8%.

Growth & Income

No dividend is on file for ACIU.

Across the complete calendar years on file, 2023 returned +145.10% and 2022 returned −58.79%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is −21.34% year to date.

Peer Comparison

AC Immune SA (ACIU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
AC Immune SA	ACIU	$245.58M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. AC Immune SA has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About AC Immune SA

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Visit website →